HOUSTON, Nov. 21, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that it has entered into a Cooperative Development Agreement with
Emphysys, an interdisciplinary technology and product development
firm just outside Boston, for
design and engineering services related to the Company's acoustical
shockwave technology.
Under the terms of the agreement, Emphysys will provide
engineering and design services related to shockwave technology for
use in dermatology and aesthetics fields to Soliton for a
three-year period.
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
Dr. Chris Capelli, Soliton
President, CEO and co-founder comments, "This partnership with
Emphysys protects Soliton's development efforts as we move through
the coming stages of commercialization. Emphysys was
instrumental to the early development of our technology and their
continued involvement helps to ensure that we launch a robust,
capable device. Our latest device iteration is designed with
both the removal of tattoos and the reduction of cellulite in mind
and we are excited to begin efforts towards a commercially viable
platform device with Emphysys' support."
Emphysys, Inc. is a technology and product development partner
to leading companies and emerging startups in the Medical Device,
Life Science, and Industrial markets. With unmatched expertise in
fundamental science, multi-modal energy generation, software
control systems, and sophisticated simulation and modeling
capabilities, the company's interdisciplinary teams of world-class
engineers and scientists focus on developing highly complex
technology and energy-based products on unprecedented time
scales.
Ali Shajii, President and CEO of Emphysys, said, "We value our
long-term partnership with Soliton and are excited to continue our
collaboration on this pioneering new technology. Our shared
mindset of developing and delivering truly differentiable products
makes this a remarkable partnership."
For more information about Emphysys, please
visit: www.emphysys.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to complete the
engineering and design of the Soliton RAP device successfully for a
future commercial launch. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Soliton has
attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/soliton-and-emphysys-enter-into-a-3-year-development-agreement-300962719.html
SOURCE Soliton, Inc.